Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: William Partmann who wrote (558)	10/29/1999 1:00:00 PM
From: All Mtn Ski	Read Replies (3) \| Respond to of 10345

A knowledgeable comment on the FDA process and the costs/benefits of the system: Message 11747718

To: William Partmann who wrote (558)	10/30/1999 9:58:00 PM
From: arnie h	Read Replies (1) \| Respond to of 10345

Presumably this is the first AD candidate coming from the Athena Neurosciences merger. As such, it promises to be a large step forward over the current FDA approved products. These simply stimulate the production of neurotransmitters which does not really address the major problems of the disease. The Athena science was at the cutting edge for both the biomechanics of the disease and a mouse model for preclinical testing. It has taken quite some time to reach the clinical stage, but it would not be surprising if their candidate represents a significant advance.